Share NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

GlobeNewsWire · NEO · November 11, 2026

NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: GlobeNewsWire ↗